Vaxart, Inc. Appoints John Harland As Chief Financial Officer
Vaxart, a privately held, clinical-stage company developing recombinant vaccines that are administered by tablet rather than by injection, today announced that John M. Harland has joined the company as chief financial officer, replacing David Madden, who served as acting CFO. Mr. Harland has more than 25 years of experience in the biotechnology and medical devices industries and has closed a wide range of financings and transactions. His appointment is effective immediately.
Help employers find you! Check out all the jobs and post your resume.